CC-115 is a potent dual inhibitor of mTOR and DNA-PK, two key proteins involved in cell growth, proliferation, and DNA repair. Its primary application lies in oncology research, particularly in the development of targeted cancer therapies. By inhibiting mTOR, CC-115 disrupts signaling pathways that drive tumor growth and survival, especially in cancers with hyperactive PI3K/AKT/mTOR pathways. Simultaneously, suppression of DNA-PK impairs the ability of cancer cells to repair double-strand DNA breaks, enhancing the effectiveness of DNA-damaging agents such as radiation or chemotherapy. This compound is widely used in preclinical studies to evaluate tumor response in various cancer types, including hematologic malignancies and solid tumors. It has shown promise in models of lymphoma, leukemia, and prostate cancer, where dual pathway inhibition leads to increased cancer cell death and reduced resistance to treatment. Due to its mechanism, CC-115 is also being explored in combination therapies to overcome treatment resistance and improve therapeutic outcomes.